Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies

Area of Science:

• Immunology
• Oncology
• Pharmacogenomics

Background:

• Therapeutic monoclonal antibodies (mAbs), including immune checkpoint inhibitors (ICIs), have transformed cancer treatment but show variable patient responses.
• Identifying predictive biomarkers is crucial for optimizing mAb therapy and patient selection.
• The efficacy of mAbs relies on interactions with Fc gamma receptors (FcγR) on innate immune cells, crucial for antibody-dependent cellular cytotoxicity (ADCC).

Purpose of the Study:

• To review the clinical significance of Fc gamma receptor (FcγR) polymorphisms in predicting patient response to monoclonal antibody (mAb) cancer therapies.
• To highlight how FcγR polymorphisms influence mAb-FcγR interactions and subsequent anti-tumor immune responses.
• To explore the role of FcγR interactions in immune checkpoint inhibitor (ICI) mechanisms within the tumor microenvironment.

Main Methods:

• Review of existing literature on FcγR polymorphisms (FcγRIIa H131R, FcγRIIIa V158F) and their association with therapeutic mAb response.
• Analysis of studies investigating FcγR-mAb binding affinity and its impact on anti-tumor activity.
• Examination of recent findings on FcγR-mediated modulation of myeloid cells by ICIs.

Main Results:

• Specific FcγRIIa and FcγRIIIa polymorphisms (e.g., H131R, V158F) are linked to differential patient responses to therapeutic mAbs.
• These polymorphisms significantly affect the binding affinity between mAbs and FcγRs, influencing in vivo efficacy.
• FcγR interactions are increasingly recognized as a mechanism by which ICIs modulate the tumor microenvironment to enhance anti-tumor activity.

Conclusions:

• Fc gamma receptor (FcγR) polymorphisms serve as valuable predictive biomarkers for response to monoclonal antibody (mAb) therapies in oncology.
• Understanding FcγR genetic variations can guide personalized treatment strategies, improving therapeutic benefit in cancer patients.
• FcγR polymorphisms are critical determinants of both direct mAb efficacy and the immunomodulatory effects of immune checkpoint inhibitors (ICIs).